Seeking Alpha

GBIM
GlobeImmune - NASDAQ

7/10/2014, 3:14 AM ET
Quote & Analysis Breaking News StockTalk
gbim chart
Today 5d 1m 3m 1y 5y 10y
52wk high:  
52wk low:  
EPS:  
PE (ttm):  
Div Rate:  
Yield:  
Market Cap:  
Volume:  
FOCUS  |  RELATED  |  TRANSCRIPTS  |  OTHER NEWS & PR
  • IPO Preview: GlobeImmune
    IPOdesktop Fri, Jun. 27

    Summary

    • GBIM is a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen┬« platform.
    • Shareholders have indicated an interest in purchasing an aggregate of up to $10 million (40%) of the IPO at the initial public offering price.
    • GBIM's accumulated deficit of -$217 million, which is very large and indicates the company's earlier business plans did not succeed.
There are no Transcripts on GBIM.
There are no News articles on GBIM.
GBIM vs. ETF Alternatives
Company Description
Currently, there's no company description for GBIM.
Country: United States
OTHER NEWS